Artivion, Inc. (NYSE:AORT) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Artivion, Inc. (NYSE:AORT) have earned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $44.1667.

Several analysts recently weighed in on AORT shares. Weiss Ratings downgraded shares of Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, June 8th. Citizens Jmp lowered their price target on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research report on Friday, May 8th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $36.00 price objective on shares of Artivion in a research note on Tuesday, June 16th. Needham & Company LLC decreased their target price on Artivion from $58.00 to $44.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Finally, Stifel Nicolaus set a $45.00 price target on shares of Artivion in a research note on Monday, June 1st.

Insiders Place Their Bets

In other Artivion news, SVP Andrew M. Green sold 44,001 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total transaction of $910,820.70. Following the sale, the senior vice president directly owned 60,259 shares in the company, valued at $1,247,361.30. This represents a 42.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.30% of the stock is currently owned by insiders.

Institutional Trading of Artivion

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in Artivion by 4.7% in the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock valued at $144,588,000 after purchasing an additional 141,030 shares during the period. Morgan Stanley increased its holdings in Artivion by 0.8% during the 4th quarter. Morgan Stanley now owns 2,256,742 shares of the company’s stock worth $102,930,000 after purchasing an additional 18,248 shares during the period. State Street Corp raised its position in Artivion by 2.9% in the 4th quarter. State Street Corp now owns 1,584,920 shares of the company’s stock valued at $72,288,000 after purchasing an additional 44,641 shares in the last quarter. Fred Alger Management LLC boosted its stake in shares of Artivion by 4.2% in the 4th quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company’s stock valued at $62,603,000 after buying an additional 55,322 shares during the period. Finally, Conestoga Capital Advisors LLC purchased a new position in shares of Artivion in the 1st quarter valued at about $43,044,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Artivion Trading Up 0.1%

NYSE:AORT opened at $24.14 on Monday. The firm has a 50 day moving average of $23.36 and a 200 day moving average of $33.81. The company has a quick ratio of 2.80, a current ratio of 3.86 and a debt-to-equity ratio of 0.48. Artivion has a 52 week low of $19.16 and a 52 week high of $48.25. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of 100.58 and a beta of 1.26.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.